Envision the Future and Take on the Power of Computing with GIGABYTE at COMPUTEX 2022
19.5.2022 17:29:00 EEST | Business Wire | Press release
GIGABYTE, a world leader in computer technology, will be presenting “Power of Computing” as its theme of the year, and exhibiting its leading products and solutions designed for various industries and fields in the upcoming COMPUTEX Taipei.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005640/en/
Envision the Future and Take on the Power of Computing with GIGABYTE at COMPUTEX 2022
GIGABYTE has curated its presentation around the theme “Power of Computing” to demonstrate that, everything from the cloud to the edge, from team collaboration to individual creation, from business applications to personal use, computing done by servers in data centers to process massive data and embedded systems in IoT and personal computers to render real-time information is the key behind groundbreaking innovations that appear in the fields of AI, cloud deployment, smart technologies, and digital content creation, etc.
Data Center is an integral part of making technological breakthroughs. GIGABYTE is a trusted pioneer in developing new server products for developers, and worked on software integrations to provide product solutions that are in line with the future of the digital age. GIGABYTE also works closely with vendors in early stages of HPC server platform development, so that system integration and optimization of SmartNICs and GPGPUs allow for heterogeneous architecture in servers to provide application-specific computing acceleration the higher computation and efficiency. In addition to supporting x86 applications using AMD and Intel processors, GIGABYTE also offers the choice of ARM servers that provide consistent data processing and encoding from the user’s terminal to edge, which not only enhances an agile response but also accelerates the development of innovations in the edge computing-piloted 5G era.
GIGABYTE is dedicated to use computing performance to accelerate innovation and advance quality of life, and has devoted effort into development of various cooling methods that includes launching products with direct liquid cooling and immersion cooling technologies to reduce the environmental impact of increased heat generated by data centers.
In the new digital age driven by AI-enabled applications, GIGABYTE has coupled its servers with MyelinTe's MLSteam platform to cluster all computing servers, storage and management nodes to facilitate resource allocation, monitoring and management, and effectively maximize resource utilization. GIGABYTE further expands its hardware experience and expertise by releasing embedded computers into everyday applications such as the fields of self-driving cars and the Internet of Vehicles. GIGABYTE's ADCU series can process massive data and make vehicle-control decisions on a real-time basis; and T-BOX can handle data and mutual communications between on-road vehicles, which is an ideal solution suitable for commercial fleet management.
Computing powers the engine for technological progression, not only to enabling successes in businesses, but also providing exhilarating personal experiences. GIGABYTE exhibits an NVIDIA Omniverse™ virtual collaboration scenario with a host-client setup using its high-performance W771-Z00 workstation and visual-spectacle BRIX mini PC; an awe-inspiring gaming showcase of flagship gaming solutions powered by Intel 12th gen processors, iF Design award-winning motherboards and monitor, and AMD Socket AM5 motherboards with advanced design and extensive features of PCIe 5.0 graphics slot and m.2 Gen5 interface; and GIGABYTE's creator/gaming laptops provide high performance with premium visual experience, with its newest flagship gaming laptop featuring the 12th Gen Intel® Core™ i9 HX series processor, offer a glimpse at the Metaverse potential.
From May 24th to 27th, GIGABYTE is primed, with an array of product solutions and applications, and ready to exhibit its hardware expertise and technology know-how, which possess the computing performance to accelerate technology innovations and uphold its vision to “Upgrade Your Life”
GIGABYTE @ COMPUTEX 2022 - https://gbte.tech/CX22
More About GIGABYTE enterprise: https://www.gigabyte.com/enterprise
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005640/en/
Contact information
Media: Michael Pao brand@gigabyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom